Hookipa Pharma Inc (NASDAQ:HOOK) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC reduced its position in Hookipa Pharma Inc (NASDAQ:HOOK) by 89.7% in the 3rd quarter, Holdings Channel reports. The firm owned 72,679 shares of the company’s stock after selling 635,149 shares during the quarter. Geode Capital Management LLC’s holdings in Hookipa Pharma were worth $313,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in shares of Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after purchasing an additional 83,800 shares during the period. Ikarian Capital LLC acquired a new stake in Hookipa Pharma in the 3rd quarter valued at about $228,000. Finally, Acadian Asset Management LLC raised its position in shares of Hookipa Pharma by 12.3% during the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after acquiring an additional 108,844 shares in the last quarter. 63.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HOOK shares. Royal Bank of Canada downgraded Hookipa Pharma from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $48.00 to $2.00 in a research note on Friday, December 20th. JMP Securities reduced their price objective on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a report on Thursday, November 21st. Finally, HC Wainwright reissued a “neutral” rating on shares of Hookipa Pharma in a report on Friday.

Hookipa Pharma Trading Down 17.2 %

NASDAQ HOOK opened at $1.78 on Tuesday. The business’s 50-day moving average price is $2.44 and its 200 day moving average price is $4.05. Hookipa Pharma Inc has a twelve month low of $1.75 and a twelve month high of $10.50. The company has a market capitalization of $21.46 million, a PE ratio of -0.48 and a beta of 0.71.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.